Addex Therapeutics Ltd

ISIN: CH0029850754 | Ticker: ADXN | LEI: 89450068Y9KVP2MQGH86

Sector: Health Care – Sub-Industry: Pharmaceuticals

Country: Switzerland

About Addex Therapeutics Ltd

Company Description

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID).

Year founded

2002

Served area

Worldwide

Headcount

Headquarters

Chemin des Aulx 12, 1228 Plan-les-Ouates – Switzerland

Filings & Publications

Insider Trades

Capital markets information

ISIN

CH0029850754

LEI

89450068Y9KVP2MQGH86

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

SIX Swiss Exchange

Contact Investor Relations department

First name*

Last name*

Your email*

Your phone number

Your company

Your message

I agree to the terms of the privacy policy.*

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.